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Abstract 
We report a case of long-term (9 years) response to 4th-line endocrine treatment with 
fulvestrant given for advanced breast cancer after no or poor response to prior endocrine 
therapies. Complete remission was achieved with full dose and maintained even after 
dose reduction due to unanticipated intensity of mucosal toxicity. Complete remission 
was temporarily lost after fulvestrant was tentatively withdrawn (63 months after 
treatment start), but was re-achieved after renewal of half-dose treatment and last 
reconfirmed 90 months after treatment start. The pharmacokinetic profile provides 
evidence to hypothesize a unique sensitivity to fulvestrant in this patient which might 
explain both: toxicity and extraordinary efficacy. 
 
Introduction 
Fulvestrant (Faslodex; AstraZeneca) is a novel steroidal estrogen receptor (ER) 
antagonist lacking agonist effects. By covalent binding to the ER, receptors are rapidly 
downregulated, resulting in a decrease of cellular ER levels and complete abrogation of 
estrogen-sensitive gene transcription [1]. The efficacy of fulvestrant in patients with 
tamoxifen-resistant disease [2, 3] and in patients progressing on aromatase inhibitors [3–
5] has been confirmed, thus giving the opportunity to extend the overall period during 
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which hormonal agents may be used in women with endocrine-responsive advanced 
breast cancer. 
However, the most efficacious dosing regimen is an ongoing debate. Two recent 
clinical trials are focusing on fulvestrant high-dose regimens (500 mg monthly) to 
optimize fulvestrant treatment. The neoadjuvant NEWEST trial [6] showed significantly 
greater biological activity benefit with high-dose fulvestrant compared to the approved 
dose. The randomized, double-blind CONFIRM (Comparison of Faslodex in Recurrent 
or Metastatic Breast Cancer) trial presented recently [7] has shown a small but statistically 
significant increase in time to progression for fulvestrant 500 mg compared with 
fulvestrant 250 mg, without increase of toxicity. 
We report a case achieving long-term complete remission under fulvestrant introduced 
after no or poor response to prior endocrine therapies, in whom the most efficacious 
dosing regimen was below the approved dose. 
Case Report 
In January 1993, a 47-year-old, premenopausal woman was diagnosed with a left breast cancer 
(pT1c(m)pN0M0) after bilateral subcutaneous mastectomy for relapsing fibroadenomas. The tumor 
was ER-positive (90%), PgR-positive (70%) as evaluated by immunohistochemistry and had a low-level 
HER2-gene amplification ratio of 2.22 (positive > 2.20) as assessed in 2007. CA 15-3 was normal. 
Axillary dissection was carried out followed by radiotherapy (50 Gy total dose), but no adjuvant 
endocrine therapy was given. 
In January 1998, distant recurrence was diagnosed in soft tissue (ER-negative, PgR-positive by 
histological assessment), in bone, pleura and lung (lymphangiosis carcinomatosa). CA 15-3 was 99 kU/l 
(normal ≤ 27 kU/l) (fig. 1). The patient was asymptomatic. Anastrozole was started as 1st-line 
endocrine treatment in a clinical trial, but discontinued after 3 months due to progression in 
pleura/lung and in the contralateral breast. CA 15-3 had further increased to 189 kU/l (fig. 1). Six cycles 
of chemotherapy with paclitaxel (175 mg/m2) and doxorubicin (60 mg/m2), every 21 days (EORTC 
10961), were given, followed by monthly pamidronate for 8 months. Partial remission for 10 months 
was achieved with normalized chest X-ray and CA 15-3. 
In June 1999, cancer progressed in the contralateral breast. She received 9 months of tamoxifen as 
2nd-line endocrine treatment, which resulted in stable disease for 6 months prior to progression (CA 
15-3 re-rising). Exemestane was started as 3rd-line endocrine treatment, but discontinued 14 days later 
due to severe allergic exanthema. 
In March 2001, cytological assessment of a further progression in the contralateral breast revealed an 
ER-positive, PgR-negative tumor and fulvestrant (250 mg intramuscular, monthly) was initiated as 4th-
line endocrine treatment. As the drug had not yet been licensed in Switzerland at that time, fulvestrant 
was initially provided free of charge through a Named Patient Program (supported by AstraZeneca). CA 
15-3 level dropped rapidly (fig. 1). Twelve months later complete remission was achieved (normal 
cervical/thoracic/abdominal computed tomography scan, disappearance of previous tracer uptake in 
bone scan). 
However, the patient experienced painful oral and vaginal dryness with loss of libido, ulcerative 
stomato-pharyngitis and an extensive thrombophlebitis of the left arm requiring temporary treatment 
interruptions. Symptomatic treatment was given in different combinations, but mucosal dryness and 
inflammation became an ongoing problem diminishing her quality of life. 
Therefore, in February 2004, we decided to continue fulvestrant at half dose (125 mg monthly). 
Mucosal symptoms improved; however, when fulvestrant was once administered in full dose by error, 
painful oral and vaginal mucositis reoccurred. 
In June 2006, complete remission was reconfirmed and fulvestrant was tentatively stopped 63 
months after the 1st injection. The patient recovered from mucosal toxicity. However, complete 
remission was lost shortly thereafter (CA 15-3 re-rising, small suspicious pleura effusion), but re-
achieved 10 months after renewal of fulvestrant (125 mg monthly) (fig. 1). 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/1
0/
20
17
 1
2:
41
:2
4 
PM
 Case Rep Oncol  2010;3:131–136 
DOI:  10.1159/000313838 
Publ ished onl ine:  Apri l  29,  2010 © 2010 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
133
In January 2008, we finally decided to determine the patient’s fulvestrant plasma concentrations 
under the 125-mg dose by the high-performance liquid chromatography (HPLC) method in the 
standard lab for fulvestrant plasma sample analyses. The maximum concentration detected was even 
below the predicted level (table 1). At follow-up in September 2008, the patient reported oral and 
vaginal dryness tolerable under symptomatic treatment. Complete remission was reconfirmed 90 
months after fulvestrant treatment start. 
Thereafter, CA 15-3 ranged between upper normal limit (UNL) and 1.3 × UNL, but so far 
progression of disease has not been confirmed on restaging. At the last follow-up in March 2010, the 
patient was doing well. Treatment will be continued. 
Discussion 
As observed in several clinical trials and case studies, some patients experience 
prolonged duration of response with fulvestrant treatment for endocrine-responsive 
advanced breast cancer [3, 8, 9]. To our knowledge, a 9-years response to 4th-line 
endocrine treatment with fulvestrant has not been reported in the literature so far. This 
case is remarkable in several aspects: First, achievement of long-lasting complete 
remission (last reconfirmed 90 months after treatment start) is very rare, especially after 
no or poor response to prior anastrozole/tamoxifen, obviously both not predictive for the 
efficacy of fulvestrant in this patient. Second, reducing the dose of fulvestrant due to 
unanticipated intensity of mucosal toxicity maintained complete remission in this case. 
Third, the obvious need for continuing treatment is also remarkable. 
We think it is important to alert oncologists to the fact that the prior response to an 
aromatase inhibitor does not appear to be predictive for the benefit of fulvestrant, an 
observation also made in a phase II trial investigating fulvestrant in patients with primary 
or acquired aromatase inhibitor-resistance [4]. 
Abram et al. presented a case with endocrine-responsive advanced breast cancer, 
which also appeared to respond better to fulvestrant than to prior endocrine therapies. 
They assumed that the intramuscular administration by a health care professional may 
have resulted in improved compliance [8]. We had no evidence of suboptimal compliance 
to oral medication in our patient. 
A Belgian study found a greater activity of fulvestrant in tumors expressing both ER 
and PgR [10]. Other investigators found fulvestrant activity not being reduced in PgR-
negative tumors [11]. In our case, hormone receptor status was ER-positive/PgR-negative 
when repeated prior to start of fulvestrant treatment, though the primary tumor was ER-
and PgR-positive. PgR expression within the tumor is known to be patchy and a sampling 
error might have led to the ER-positive, PgR-negative result in the immunocytochemical 
analysis of the fine needle aspiration material. 
Tumors for which fulvestrant therapy might be particularly appropriate are those ER-
positive tumors with HER2 overexpression assuming ligand-independent ER activation 
seems to be a key feature [11–13]. However, available data are conflicting. In our case, 
HER2 amplification with a ratio of 2.22 was low and unlikely to contribute to the 
superiority of fulvestrant compared to anastrozole and tamoxifen by the above-
mentioned mechanism. 
Several large trials have shown that fulvestrant is well tolerated [2, 3, 4, 14]. Our patient 
experienced unusually severe mucosal toxicity together with complete remission under 
the approved 250-mg dose, but clearly less toxicity while maintaining complete remission 
under a 125-mg dose. Mucosal toxicity cannot be explained by the patient’s medical 
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history. The pharmacokinetic profile excluded faster absorption or a variation in drug 
metabolism which theoretically could have contributed to the observed toxicity and 
efficacy (table 1). Her fulvestrant plasma concentrations were below the observed mean 
for a 250-mg dose [15] and, importantly, even below the predicted mean for a 125-mg 
dose. 
We therefore hypothesize an extraordinary sensitivity, but not a metabolic 
phenomenon as a key factor in the observations made in this case. This might explain 
toxicity, efficacy and the need for continuing treatment. 
This observation is of particular interest in the ongoing fulvestrant dosing debate: our 
case might serve as a basis for future strategies investigating individual dosing as a 
promising approach for optimizing fulvestrant treatment. 
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Table 1. Patient’s fulvestrant plasma concentrations at 125-mg dose (steady state) 
 Pre-dose trough Day 8 peak Day 15 Day 22 Day 29 
Concentration, ng/ml 3.44 (3.6 ± 0.6)a 5.17 (7.7 ± 1.0)a 4.10 4.22 3.04 
ª Predicted fulvestrant concentrations at 125-mg dose (steady state) at trough and at peak, AstraZeneca 
Data on File. Predictions are based upon a pharmacokinetic model used to describe a phase III breast 
cancer population [16]. 
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Fig. 1. Tumor marker and given treatments since recurrence of disease. 1 Endocrine treatments and 
chemotherapy (anastrozole Jan98, chemotherapy Apr98, tamoxifen Jun99, exemestane Apr00). 2 
Fulvestrant (half dose since Feb04). 3 Fulvestrant stopped. 4 Fulvestrant re-started (half dose). 
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